Clinical Trials

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

492 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Recruiting

70 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

1,503 enrolled

Phase 2/3 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

300 enrolled

Other hematologic neoplasmPlasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00466674 2025-12-19

IFM 2005-03

Phase 2 Completed

13 enrolled

Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1 Recruiting

Neoplasms, Plasma Cell

NCT04268199 2025-12-15

EASE

100 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04680468 2025-12-15

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

41 enrolled

Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

49 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

Phase NA Active not recruiting

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05763563 2025-12-04

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Leukemia, Lymphoma, Neoplasms, Plasma Cell

NCT06947083 2025-12-03

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

39 enrolled

Neoplasms, Plasma Cell

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02244125 2025-11-24

PCD

Phase 2 Completed

100 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

4 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Phase 1/2 Recruiting

Neoplasms, Plasma Cell

NCT05336383 2025-10-09

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07202052 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Phase 2/3 Recruiting

900 enrolled

Infections, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms, Plasma Cell

NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Phase 2/3 Recruiting

900 enrolled

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Phase 2/3 Recruiting

900 enrolled

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06487247 2025-09-17

HEME Home Transfusion Program

Phase NA Recruiting

700 enrolled

Hematologic Diseases, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT04862676 2025-09-10

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

Phase EARLY_PHASE1 Completed

29 enrolled

Phase 1/2 Active not recruiting

Neoplasms, Plasma Cell

NCT03162536 2025-09-08

ARQ 531-101

190 enrolled

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06986434 2025-09-03

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Phase EARLY_PHASE1 Not yet recruiting

Recurrence, Neoplasms, Plasma Cell

NCT01810588 2025-09-02

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

270 enrolled 13 charts

Lymphoma, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT06523699 2025-08-28

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

Phase 1 Recruiting

Classical hematologyPlasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02066454 2025-08-13

MYELAXAT

Phase 3 Completed

108 enrolled

Neoplasms, Plasma Cell, Venous Thromboembolism

NCT03314636 2025-08-08

CONPET

53 enrolled

Neoplasms, Plasma Cell

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04194840 2025-08-05

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Phase NA Completed

BreastLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT03862131 2025-07-29

PROACT

Phase 2 Terminated

49 enrolled 12 charts

Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Sarcoma, Neoplasms, Plasma Cell, Cardiotoxicity

NCT07077330 2025-07-22

CAR19BCMA

Phase EARLY_PHASE1 Not yet recruiting